Optimizing mHSPC Treatment: The Evidence for Early Intensification - European Medical Journal

Optimizing mHSPC Treatment: The Evidence for Early Intensification


Watch Professor Fred Saad, Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center, as he describes the evolution of standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) from androgen-deprivation therapy (ADT) alone to combination treatment with novel hormonal therapy (NHT). Discover the level 1 evidence supporting the use of NHTs across mHSPC patient populations, and the scientific rationale for early intensification to extend overall survival, delay disease progression, and maintain quality of life for men living with the disease.

Visit the KNOW platform to learn more and access additional on-demand content: https://webapp.spotme.com/login/eventspace/KNOW. KNOW is an Astellas-sponsored HCP educational program that provides insights from leading experts to improve outcomes for prostate cancer patients.

This video has been developed and funded by Astellas Pharma Ltd and is intended for healthcare professionals only. All healthcare professionals should refer to their own country-specific prescribing information for products mentioned during this video. Adverse-event reporting details are available in the video.

Professor Saad has received honoraria as a consultant and funding for research from: Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Bayer, Janssen, Myovant, Sanofi, and Pfizer.

MAT-ABC-OPC-2023-00012 | April 2023

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?